ProBioGen AG
End-to-end CDMO services for proteins, viral vectors & vaccines
ProBioGen AG is a CDMO offering cell line development, process development, GMP manufacturing and analytical services for proteins, antibodies, viral vectors and vaccines. It also provides technology platforms for biopharmaceutical manufacturing. Headquartered in Berlin, Germany.
Modalities
Development & manufacturing
Structured CDMO capabilities from verified public sources.
Development (D)
Manufacturing (M)
Biologics / bioreactor infrastructure
- Expression systems
- MammalianViral Vector
Services
- Analytical Method Development & Validation
- ICH Stability Studies
- EU EMA Regulatory Strategy
- US FDA Regulatory Strategy
- Cell-Line Development
- Process Development
- Biologics Development & Manufacturing
- Recombinant Protein Manufacturing
- Monoclonal Antibody (mAb) Manufacturing
- Viral Vector Manufacturing
- AAV Manufacturing
- Lentiviral Vector Manufacturing
- Vaccine Manufacturing
- Technology Transfer
- CMC Analytical Development
- Quality Control Testing
- Stability Testing & Storage
- Formulation Development
- CMC Regulatory Submission Support
Indications
About this organization
ProBioGen AG describes itself as a fully integrated contract development and manufacturing organization (CDMO) and technology provider for biopharmaceuticals, viral vectors, and vaccines.
Services for proteins and antibodies
- Cell line development and cell banking
- Process development
- GMP manufacturing
- Technology transfer
- Analytics and bioassays
- Biosimilars and biobetters support
Services for viral vectors and vaccines
- Producer cell line development
- Process development
- GMP manufacturing, including AAV, lentivirus, and poxvirus production
- Quality analytics
Quality and analytical services
- Quality systems
- Regulatory support
- Formulation development
- Release testing and stability studies
- Bioassays
Proprietary technologies
- CHO.RiGHT producer cell lines, DirectedLuck transposase system, and GlymaxX ADCC/glycoengineering for proteins
- MVA-CR19 vector platform, Lenti.RiGHT production system, and AGE1.CR.pIX and AGE1.CR.ReX designer cell lines for viral vectors and vaccines
The company states that its proprietary technologies are used to deliver high process yields and potency and quality for client products.
Subsidiary ProBioGen announced the formation of MiGenTra, a subsidiary established with Minapharm Pharmaceuticals. MiGenTra focuses on product development and commercialization in biosimilars, cell and gene therapies, and vaccines for Egypt, the Middle East, and Africa, with a principal manufacturing plant in Cairo.
Certifications
Locations
Berlin
Berlin · Berlin · Germany
Cairo
Cairo · Cairo Governorate · Egypt
Headquarters
Berlin · Berlin · Germany
Office
Berlin · Berlin · Germany
Recent news about ProBioGen AG
Related companies
Similar profiles by shared services, modalities, and capabilities.
Boston Institute of Biotechnology, LLC- Analytical Method Development & Validation
- ICH Stability Studies
Minaris Advanced Therapies- Cell-Line Development
- Process Development
Enzene Biosciences- Cell-Line Development
- Process Development
FUJIFILM Biotechnologies- Cell-Line Development
- Process Development
Charles River Laboratories- Cell-Line Development
- Process Development
Capitol Biologics- Cell-Line Development
- Process Development
Asimov- Cell-Line Development
- Process Development
AGC Biologics- Cell-Line Development
- Process Development
Submit a verified review for this organization.
Markdown mirror: /companies/probiogen.md